Bayer's Retinal Pioneers Programme
Access resources developed in collaboration with thought leaders in ophthalmology
Established in 2018, Retinal Pioneers is a promotional programme organised and funded by Bayer, designed to contribute towards the evolution of retinal knowledge and catalyse innovation in medical retina. As part of the programme, this Retinal Pioneers Hub provides a source of on-demand, educational resources developed in collaboration with national and international thought leaders in ophthalmology. Materials on this hub are available throughout the year, with new content released quarterly.
Retinal Pioneers Summit (RPS)
Retinal Pioneers Summit is an annual meeting designed to enable UK ophthalmologists to explore the latest innovations and scientific and clinical advancements in the management of medical retina conditions. We’re pleased to confirm that
Key highlights poster
Read
- Improving patient care and clinician well-being
- Clinical updates with aflibercept 8 mg
- Current and future technologies in medical retina
EYLEA (aflibercept) 8 mg: Real-world insights
These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg in clinical practice for licensed indications. Each video includes early experiences and key learnings from real-world cases, designed to aid understanding and help facilitate best practice for EYLEA 8 mg in UK clinical practice.
In this video, Kirsty discusses current challenges in medical retina services in Scotland and provides insights into the implementation, outcomes, practical considerations and overall impact of using EYLEA 8 mg in treating patients with nAMD.
Prescribing information for EYLEA® (aflibercept)
Bitesize OCT knowledge checkers
Test your knowledge of OCT disease biomarkers in this series of OCT images and associated knowledge-checker questions provided by
Key developments relating to EYLEA (aflibercept) 8 mg
The SPECTRUM study
This poster explores the efficacy and safety profile of EYLEA 8 mg in treatment-naïve and previously treated patients with nAMD and DMO in this global real-world study.
Eye on the Horizon podcast series
Listen to the eighth episode in this podcast series, in which
Eye on the Horizon Podcast Series
Join
Challenging cases in medical retina
These case study posters feature challenging scenarios across multiple indications in medical retina, provided by a range of clinicians from across the UK. Each poster includes key information from one or two short case studies and invites you to reflect on the steps that you would follow to manage the same cases.
Challenging cases in medical retina: A UK case study
Talking head video series with Dr SriniVas Sadda: Advances in imaging technologies
Imaging expert Dr SriniVas Sadda, Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute and Professor of Ophthalmology at UCLA, USA, explores advances in imaging in medical retina in this talking head video series. In each 10-minute video, Dr Sadda provides a detailed overview of a different imaging technology, including its advantages and disadvantages, as well as its practicalities in clinical practice.
Learn about the basic principles and potential applications of FLIO in medical retina.
Prescribing information for EYLEA® (aflibercept)
DMO, diabetic macular oedema. FLIO, Fluorescence Lifetime Imaging Ophthalmoscopy. HCP, healthcare professional. nAMD, neovascular age-related macular degeneration. NHS, National Health Service. OCT, optical coherence tomography. RVO, retinal vein occlusion. UCLA, University of California, Los Angeles.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO). For full details please refer to Summary of Product Characteristics.
Prescribing information for EYLEA® (aflibercept)
PP-EYL-GB-2908 | August 2025